Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAVVY vaginal gel
- Development stage
- Phase 3
- Lead developer
- Cellegy Pharmaceuticals
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Vaginal
01
Overview
SAVVY vaginal gel is a microbicide containing 1.0% C31G, an equimolar mixture of alkyl dimethyl glycine and alkyl dimethyl amine oxide. It is designed for the prevention of male-to-female transmission of HIV. Its mechanism of action against HIV involves disrupting the outer membrane of enveloped HIV, acting as a virucide by lowering the surface tension of the pathogen.
- Brand names
- SAVVY
- Other names
- 1.0% C31G (SAVVY) vaginal gel
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on SAVVY vaginal gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAVVY vaginal gel.